COMPARATOR TRIAL FOR MODERATE TO SEVERE ECZEMA

Adults aged 18 years or older who have a diagnosis of eczema / atopic dermatitis (AD) that has been present for 1 year or longer, may qualify for this clinical research trial and receive investigational injected treatment (active study drug) or comparator medication.
Eligible participants must have moderate to severe eczema / atopic dermatitis (AD) affecting 10% or more of their body surface area (this equates to 10 palm prints). A history of poor response to treatment with topical medications, or medical determination that topical therapies are inadvisable, is also required. A non-medicated over-the-counter emollient/moisturizer must be used throughout the study.

Participants will have regular visits with an experienced research team. There is no cost to participate, and participants will be reimbursed for study-related expenses. Participants will be asked to visit the study centre about 24 times over a period of about 82 weeks.

For more detailed information about this clinical trial, please visit:

Study Details | NCT07027527 | An Active Comparator Safety Study Evaluating the Combination of APG777 + APG990 in Moderate-to-Severe Atopic Dermatitis | ClinicalTrials.gov

Principal Investigator
A/Prof Peter Foley

Sub Investigators

Study Coordinator
Tracy Mallett
Phone Number: 03 9623 9439
Email: [email protected]